Although KRAS can directly activate PI3K signaling by binding to the p110-PI3K subunit, there is increasing evidence that PI3K activation, following MEK inhibition, is correlated with RTK activity, providing the foundation for the use of RTK inhibitors in KRAS-mutant CRC [36]. This evidence concerns the gene PIK3CA and colorectal carcinoma.